990 related articles for article (PubMed ID: 26408156)
1. Endocannabinoids and Their Pharmacological Actions.
Pertwee RG
Handb Exp Pharmacol; 2015; 231():1-37. PubMed ID: 26408156
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
[TBL] [Abstract][Full Text] [Related]
3. Why do cannabinoid receptors have more than one endogenous ligand?
Di Marzo V; De Petrocellis L
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3216-28. PubMed ID: 23108541
[TBL] [Abstract][Full Text] [Related]
4. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.
Pertwee RG; Howlett AC; Abood ME; Alexander SP; Di Marzo V; Elphick MR; Greasley PJ; Hansen HS; Kunos G; Mackie K; Mechoulam R; Ross RA
Pharmacol Rev; 2010 Dec; 62(4):588-631. PubMed ID: 21079038
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte Colony-Stimulating Factor Enhances Brain Repair Following Traumatic Brain Injury Without Requiring Activation of Cannabinoid Receptors.
Song S; Kong X; Borlongan C; Sava V; Sanchez-Ramos J
Cannabis Cannabinoid Res; 2021; 6(1):48-57. PubMed ID: 33614952
[No Abstract] [Full Text] [Related]
6. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
Sharir H; Console-Bram L; Mundy C; Popoff SN; Kapur A; Abood ME
J Neuroimmune Pharmacol; 2012 Dec; 7(4):856-65. PubMed ID: 22454039
[TBL] [Abstract][Full Text] [Related]
7. The pharmacology of cannabinoid receptors and their ligands: an overview.
Pertwee RG
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
[TBL] [Abstract][Full Text] [Related]
8. Targeting the endocannabinoid system as a potential anticancer approach.
Schwarz R; Ramer R; Hinz B
Drug Metab Rev; 2018 Feb; 50(1):26-53. PubMed ID: 29390896
[TBL] [Abstract][Full Text] [Related]
9. Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor.
Steffens M; Zentner J; Honegger J; Feuerstein TJ
Biochem Pharmacol; 2005 Jan; 69(1):169-78. PubMed ID: 15588725
[TBL] [Abstract][Full Text] [Related]
10. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.
Di Marzo V
Pharmacol Res; 2009 Aug; 60(2):77-84. PubMed ID: 19559360
[TBL] [Abstract][Full Text] [Related]
11. An introduction to the endocannabinoid system: from the early to the latest concepts.
De Petrocellis L; Di Marzo V
Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):1-15. PubMed ID: 19285257
[TBL] [Abstract][Full Text] [Related]
12. Modern approaches to the development of synthetic cannabinoid receptor probes.
Saldaña-Shumaker SL; Grenning AJ; Cunningham CW
Pharmacol Biochem Behav; 2021 Apr; 203():173119. PubMed ID: 33508249
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of cannabinoid receptor ligands: current status.
Singh J; Budhiraja S
Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
[TBL] [Abstract][Full Text] [Related]
14. Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow.
Wu J
Acta Pharmacol Sin; 2019 Mar; 40(3):297-299. PubMed ID: 30670816
[No Abstract] [Full Text] [Related]
15. Activation of CB
Karpińska O; Baranowska-Kuczko M; Kloza M; Ambroz Ewicz E; Kozłowski T; Kasacka I; Malinowska B; Kozłowska H
Am J Physiol Regul Integr Comp Physiol; 2017 Jun; 312(6):R883-R893. PubMed ID: 28356298
[TBL] [Abstract][Full Text] [Related]
16. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?
Bermudez-Silva FJ; Viveros MP; McPartland JM; Rodriguez de Fonseca F
Pharmacol Biochem Behav; 2010 Jun; 95(4):375-82. PubMed ID: 20347862
[TBL] [Abstract][Full Text] [Related]
17. Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.
Duncan M; Millns P; Smart D; Wright JE; Kendall DA; Ralevic V
Br J Pharmacol; 2004 Jun; 142(3):509-18. PubMed ID: 15148262
[TBL] [Abstract][Full Text] [Related]
18. Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review.
Hryhorowicz S; Kaczmarek-Ryś M; Zielińska A; Scott RJ; Słomski R; Pławski A
Front Immunol; 2021; 12():790803. PubMed ID: 35003109
[TBL] [Abstract][Full Text] [Related]
19. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.
Pertwee RG
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3353-63. PubMed ID: 23108552
[TBL] [Abstract][Full Text] [Related]
20. Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB
Karwad MA; Couch DG; Wright KL; Tufarelli C; Larvin M; Lund J; O'Sullivan SE
Biochem Pharmacol; 2019 Oct; 168():465-472. PubMed ID: 31325449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
